FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049820493> ?p ?o ?g. }

• W2049820493 endingPage "920" @default.
• W2049820493 startingPage "913" @default.
• W2049820493 abstract "BackgroundThis study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC).MethodsMen with no prior chemotherapy (group A) and men with docetaxel (Taxotere)-resistant prostate cancer (group B) were treated with sunitinib. The primary end point was confirmed 50% prostate-specific antigen (PSA) decline. Secondary end points included objective response rate and safety. Serum-soluble biomarkers were measured.ResultsSeventeen men were enrolled in each group. One confirmed PSA response was observed in each group, and an additional eight men and seven men had stable PSA at week 12 in groups A and B, respectively. Improvements in imaging were observed in the absence of post-treatment PSA declines. Common adverse effects included fatigue, nausea, diarrhea, myelosuppression and transaminase elevation. Significant changes following sunitinib treatment were observed in serum-soluble biomarkers including soluble vascular endothelial growth factor receptor-2, platelet-derived growth factor aa, placental growth factor and leptin.ConclusionsSunitinib monotherapy resulted in few confirmed 50% post-treatment declines in PSA in men with CRPC. Serum markers of angiogenesis confirmed on-target effects of sunitinib. Assessments of radiographic disease status were often discordant with changes in PSA, indicating that alternate end points are important in future trials." @default.
• W2049820493 created "2016-06-24" @default.
• W2049820493 creator A5017334876 @default.
• W2049820493 creator A5017925159 @default.
• W2049820493 creator A5018292930 @default.
• W2049820493 creator A5023563011 @default.
• W2049820493 creator A5028789952 @default.
• W2049820493 creator A5031172082 @default.
• W2049820493 creator A5043671466 @default.
• W2049820493 creator A5052884921 @default.
• W2049820493 creator A5054383262 @default.
• W2049820493 creator A5056361969 @default.
• W2049820493 date "2009-05-01" @default.
• W2049820493 modified "2023-10-16" @default.
• W2049820493 title "Phase II study of sunitinib in men with advanced prostate cancer" @default.
• W2049820493 cites W1975936849 @default.
• W2049820493 cites W1984696385 @default.
• W2049820493 cites W1988698591 @default.
• W2049820493 cites W1994327821 @default.
• W2049820493 cites W2019234769 @default.
• W2049820493 cites W2026790929 @default.
• W2049820493 cites W2036245537 @default.
• W2049820493 cites W2043103956 @default.
• W2049820493 cites W2045679498 @default.
• W2049820493 cites W2066209913 @default.
• W2049820493 cites W2080439368 @default.
• W2049820493 cites W2088515900 @default.
• W2049820493 cites W2104648430 @default.
• W2049820493 cites W2105677187 @default.
• W2049820493 cites W2111796479 @default.
• W2049820493 cites W2119402609 @default.
• W2049820493 cites W2120292596 @default.
• W2049820493 cites W2126426760 @default.
• W2049820493 cites W2126565162 @default.
• W2049820493 cites W2150452646 @default.
• W2049820493 cites W2155679349 @default.
• W2049820493 cites W2164782357 @default.
• W2049820493 cites W2166788033 @default.
• W2049820493 cites W2167331614 @default.
• W2049820493 cites W2262468821 @default.
• W2049820493 cites W2278076254 @default.
• W2049820493 cites W2513729771 @default.
• W2049820493 doi "https://doi.org/10.1093/annonc/mdp111" @default.
• W2049820493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2674960" @default.
• W2049820493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19403935" @default.
• W2049820493 hasPublicationYear "2009" @default.
• W2049820493 type Work @default.
• W2049820493 sameAs 2049820493 @default.
• W2049820493 citedByCount "137" @default.
• W2049820493 countsByYear W20498204932012 @default.
• W2049820493 countsByYear W20498204932013 @default.
• W2049820493 countsByYear W20498204932014 @default.
• W2049820493 countsByYear W20498204932015 @default.
• W2049820493 countsByYear W20498204932016 @default.
• W2049820493 countsByYear W20498204932017 @default.
• W2049820493 countsByYear W20498204932018 @default.
• W2049820493 countsByYear W20498204932020 @default.
• W2049820493 countsByYear W20498204932021 @default.
• W2049820493 countsByYear W20498204932022 @default.
• W2049820493 countsByYear W20498204932023 @default.
• W2049820493 crossrefType "journal-article" @default.
• W2049820493 hasAuthorship W2049820493A5017334876 @default.
• W2049820493 hasAuthorship W2049820493A5017925159 @default.
• W2049820493 hasAuthorship W2049820493A5018292930 @default.
• W2049820493 hasAuthorship W2049820493A5023563011 @default.
• W2049820493 hasAuthorship W2049820493A5028789952 @default.
• W2049820493 hasAuthorship W2049820493A5031172082 @default.
• W2049820493 hasAuthorship W2049820493A5043671466 @default.
• W2049820493 hasAuthorship W2049820493A5052884921 @default.
• W2049820493 hasAuthorship W2049820493A5054383262 @default.
• W2049820493 hasAuthorship W2049820493A5056361969 @default.
• W2049820493 hasBestOaLocation W20498204931 @default.
• W2049820493 hasConcept C121608353 @default.
• W2049820493 hasConcept C126322002 @default.
• W2049820493 hasConcept C126894567 @default.
• W2049820493 hasConcept C143998085 @default.
• W2049820493 hasConcept C167734588 @default.
• W2049820493 hasConcept C197934379 @default.
• W2049820493 hasConcept C2777025900 @default.
• W2049820493 hasConcept C2778375690 @default.
• W2049820493 hasConcept C2779490328 @default.
• W2049820493 hasConcept C2780192828 @default.
• W2049820493 hasConcept C2781190966 @default.
• W2049820493 hasConcept C71924100 @default.
• W2049820493 hasConceptScore W2049820493C121608353 @default.
• W2049820493 hasConceptScore W2049820493C126322002 @default.
• W2049820493 hasConceptScore W2049820493C126894567 @default.
• W2049820493 hasConceptScore W2049820493C143998085 @default.
• W2049820493 hasConceptScore W2049820493C167734588 @default.
• W2049820493 hasConceptScore W2049820493C197934379 @default.
• W2049820493 hasConceptScore W2049820493C2777025900 @default.
• W2049820493 hasConceptScore W2049820493C2778375690 @default.
• W2049820493 hasConceptScore W2049820493C2779490328 @default.
• W2049820493 hasConceptScore W2049820493C2780192828 @default.
• W2049820493 hasConceptScore W2049820493C2781190966 @default.
• W2049820493 hasConceptScore W2049820493C71924100 @default.
• W2049820493 hasFunder F4320306163 @default.
• W2049820493 hasIssue "5" @default.

• next